In the wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently
seen as a potential therapeutic option for patients with cancer who do not respond or fail to …

The microenvironment characteristics of solid tumors, renowned as barriers that harshly
impeded many drug-delivery approaches, were precisely studied, investigated, categorized …

In view of the advancement in the understanding about the most diverse types of cancer and
consequently a relentless search for a cure and increased survival rates of cancer patients …

Decorin (DCN), an extracellular matrix (ECM) protein, belongs to the small leucine-rich
proteoglycan family. As a pluripotent molecule, DCN regulates the bioactivities of cell growth …

Glioblastoma (GBM) is an immunosuppressive, lethal brain tumor. Despite advances in
molecular understanding and therapies, the clinical benefits have remained limited, and the …

Collagen is the most abundant protein in animals. Interactions between tumor cells and
collagen influence every step of tumor development. Type I collagen is the main fibrillar …

Despite significant improvement in modalities for treatment of cancer that led to a longer
survival period, the death rate of patients with solid tumors has not changed during the last …

Oncolytic virotherapy is a therapeutic approach that uses replication-competent viruses to
kill cancers. The ability of oncolytic viruses to selectively replicate in cancer cells leads to …

Oncolytic virotherapy is a promising alternative to conventional treatment, yet systemic
delivery of these viruses to tumors remains a major challenge. In this regard, mesenchymal …

It has been intensively reported that the immunosuppressive tumor microenvironment (TME)
results in tumor resistance to immunotherapy, especially immune checkpoint blockade and …